News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Proposes to Disapprove the Use of the Drug Novartis AG's Lucentis; Diabetes Groups Outraged



7/19/2011 7:32:05 AM

Novartis says it is “disappointed” with health watchdog NICE’s decision not to recommend Lucentis for the treatment of eye problems due to diabetic macular oedema (DMO). NICE decided the VEGF drug Lucentis (ranibizumab) did not offer better value for money than laser treatment, which is the current standard of care, for patients in England and Wales. It also suggested Novartis’ costing model was flawed. “By not accounting in its submission for the need to treat both eyes in a proportion of people with DMO, the manufacturer significantly underestimated the cost of treatment,” insisted NICE chief executive Andrew Dillon.



comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES